HLA immunogenotype determines persistent human papillomavirus virus infection in HIV-infected patients receiving antiretroviral treatment

Abstract

A proportion of human immunodeficiency virus (HIV)-infected patients develop persistent, stigmatizing human papillomavirus (HPV)-related cutaneous and genital warts and anogenital (pre)cancer. This is the first study to investigate immunogenetic variations that might account for HPV susceptibility and the largest to date to categorize the HPV types associated with cutaneous warts in HIV-positive patients. The HLA class I and II allele distribution was analyzed in 49 antiretroviral (ART)-treated HIVpositive patients with persistent warts, 42 noninfected controls, and 46 HIV-positive controls. The allele HLA-B∗44 was more frequently identified in HIV-positive patients with warts (P = .004); a susceptible haplotype (HLA-B∗44, HLA-C∗05; P = .001) and protective genes (HLA-DQB1∗06; P = .03) may also contribute. Cutaneous wart biopsy specimens from HIV-positive patients harbored common wart types HPV27/57, the unusual wart type HPV7, and an excess of Betapapillomavirus types (P = .002), compared with wart specimens from noninfected controls. These findings suggest that HLA testing might assist in stratifying those patients in whom vaccination should be recommended.